Curis Inc
CRIS1.030USD
+0.119+13.11%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
13.12MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Curis Inc Unternehmen
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). The Erivedge, is a commercialized orally administered small molecule Hedgehog signaling pathway antagonist. Its other clinical programs include Fimepinostat and CA-170. CA-170 is an oral small molecule drug candidate that targets V-domain Ig Suppressor of T-cell Activation, or VISTA, and PDL1 immune checkpoint proteins.
Curis Inc Informationen
BörsenkürzelCRIS
Name des UnternehmensCuris Inc
IPO-datumAug 01, 2000
CEODentzer (James E)
Anzahl der mitarbeiter33
WertpapierartOrdinary Share
GeschäftsjahresendeAug 01
Addresse128 Spring Street
StadtLEXINGTON
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl02421
Telefon16175036500
Websitehttps://www.curis.com/
BörsenkürzelCRIS
IPO-datumAug 01, 2000
CEODentzer (James E)
Führungskräfte von Curis Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. James E. Dentzer
Mr. James E. Dentzer
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
8.39K
+2310.00%
Ms. Diantha Duvall
Ms. Diantha Duvall
Chief Financial Officer
Chief Financial Officer
4.90K
+4255.00%
Dr. Kenneth I. Kaitin, Ph.D.
Dr. Kenneth I. Kaitin, Ph.D.
Independent Director
Independent Director
1.41K
--
Mr. Martyn D. Greenacre
Mr. Martyn D. Greenacre
Independent Chairman of the Board
Independent Chairman of the Board
1.30K
--
Dr. Marc Rubin, M.D.
Dr. Marc Rubin, M.D.
Independent Director
Independent Director
--
--
Dr. John A. Hohneker, M.D.
Dr. John A. Hohneker, M.D.
Independent Director
Independent Director
--
--
Dr. Anne Borgman, M.D.
Dr. Anne Borgman, M.D.
Independent Director
Independent Director
--
--
Dr. Jonathan Zung, Ph.D.
Dr. Jonathan Zung, Ph.D.
Chief Development Officer
Chief Development Officer
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. James E. Dentzer
Mr. James E. Dentzer
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
8.39K
+2310.00%
Ms. Diantha Duvall
Ms. Diantha Duvall
Chief Financial Officer
Chief Financial Officer
4.90K
+4255.00%
Dr. Kenneth I. Kaitin, Ph.D.
Dr. Kenneth I. Kaitin, Ph.D.
Independent Director
Independent Director
1.41K
--
Mr. Martyn D. Greenacre
Mr. Martyn D. Greenacre
Independent Chairman of the Board
Independent Chairman of the Board
1.30K
--
Dr. Marc Rubin, M.D.
Dr. Marc Rubin, M.D.
Independent Director
Independent Director
--
--
Dr. John A. Hohneker, M.D.
Dr. John A. Hohneker, M.D.
Independent Director
Independent Director
--
--
Umsatzaufteilung
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Sun, Nov 16
Aktualisiert: Sun, Nov 16
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Bleichroeder LP
8.78%
Armistice Capital LLC
7.57%
Satterfield (Thomas A Jr)
6.86%
Citi Investment Research (US)
4.49%
M28 Capital Management LP
4.03%
Andere
68.27%
Aktionäre
Aktionäre
Anteil
Bleichroeder LP
8.78%
Armistice Capital LLC
7.57%
Satterfield (Thomas A Jr)
6.86%
Citi Investment Research (US)
4.49%
M28 Capital Management LP
4.03%
Andere
68.27%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
19.27%
Hedge Fund
9.74%
Individual Investor
6.99%
Research Firm
4.70%
Investment Advisor/Hedge Fund
1.84%
Andere
57.45%
Institutionelle Beteiligung
Aktualisiert: Mon, Dec 8
Aktualisiert: Mon, Dec 8
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
83
4.63M
39.24%
--
2025Q3
85
4.63M
39.84%
+335.60K
2025Q2
95
4.29M
47.96%
-381.52K
2025Q1
104
4.67M
35.08%
+1.00M
2024Q4
110
3.21M
29.04%
+1.19M
2024Q3
121
2.02M
47.43%
-296.29K
2024Q2
144
2.32M
48.36%
+147.50K
2024Q1
219
2.10M
55.49%
-1.17M
2023Q4
242
2.06M
62.43%
-75.74K
2023Q3
258
2.13M
59.12%
+333.55K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Bleichroeder LP
1.14M
8.78%
+100.00K
+9.66%
Sep 30, 2025
Armistice Capital LLC
978.19K
7.57%
+78.27K
+8.70%
Sep 30, 2025
Satterfield (Thomas A Jr)
886.71K
6.86%
+274.49K
+44.84%
Mar 31, 2025
Citi Investment Research (US)
581.12K
4.49%
+489.25K
+532.53%
Sep 30, 2025
M28 Capital Management LP
521.06K
4.03%
--
--
Sep 30, 2025
The Vanguard Group, Inc.
367.62K
2.84%
+64.43K
+21.25%
Sep 30, 2025
CM Management, LLC
325.00K
2.51%
+105.00K
+47.73%
Sep 30, 2025
Renaissance Technologies LLC
175.51K
1.36%
+75.04K
+74.69%
Sep 30, 2025
Geode Capital Management, L.L.C.
94.67K
0.73%
+9.36K
+10.98%
Sep 30, 2025
Focused Wealth Management, Inc.
79.20K
0.61%
+20.00K
+33.77%
Sep 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
iShares Micro-Cap ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
Anteil0%
Avantis US Small Cap Equity ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Sep 28, 2023
Merger
20→1
Sep 28, 2023
Merger
20→1
Sep 28, 2023
Merger
20→1
Sep 28, 2023
Merger
20→1
Datum
Ex-Dividendentag
Art
Verhältnis
Sep 28, 2023
Merger
20→1
Sep 28, 2023
Merger
20→1
Sep 28, 2023
Merger
20→1
Sep 28, 2023
Merger
20→1
